CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter.

Choudhury SR, Cui Y, Lubecka K, Stefanska B, Irudayaraj J. · 2016

Read CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter. by Choudhury SR, Cui Y, Lubecka K, Stefanska B, Irudayaraj J. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5216816.txt.

Introduction

Samrat Roy Choudhury, Yi Cui, Katarzyna Lubecka, Barbara Stefanska, and Joseph Irudayaraj built a targeted demethylation tool in Oncotarget in 2016. In many cancers, tumour-suppressor genes are switched off when their promoter regions gain too much methylation, a chemical mark on DNA. BRCA1, a gene that normally helps guard against breast cancer, served as their test case.

The tool fuses a disabled Cas9 protein, which can be guided to a chosen DNA site but cannot cut, to the active part of TET1, an enzyme that removes methylation marks. Guide RNAs steered the fusion to the BRCA1 promoter, where it stripped methylation at the target site and switched the gene back on. A rise in an intermediate mark at the most changed site confirmed the enzyme was doing the work. The design is modular, so other editing enzymes can be swapped in.

Catalog record

CREATORChoudhury SR, Cui Y, Lubecka K, Stefanska B, Irudayaraj J.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5216816

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter By Samrat Roy Choudhury, Yi Cui, Katarzyna Lubecka, Barbara Stefanska, Joseph Irudayaraj Published in: Oncotarget DOI: 10.18632/oncotarget.10234 ABSTRACT Abstract DNA hypermethylation at the promoter of tumour-suppressor genes is tightly correlated with their transcriptional repression and recognized as the hallmark of majority of cancers. Epigenetic silencing of tumour suppressor genes impairs their cellular functions and activates a cascade of events driving cell transformation and cancer progression. Here, we examine site-specific and spatiotemporal alteration in DNA methylation at a target region in BRCA1 gene promoter, a model tumour suppressor gene. We have developed a programmable CRISPR-Cas9 based demethylase tool containing the deactivated Cas9 (dCas9) fused to the catalytic domain (CD) of Ten-Eleven Translocation (TET) dioxygenase1 (TET1CD). The fusion protein selectively demethylates targeted regions within BRCA1 promoter as directed by the designed single-guide RNAs (sgRNA), leading to the transcriptional up-regulation of the gene. We also noticed the increment in 5-hydroxymethylation content (5-hmC) at the target DNA site undergoing the most profound demethylation. It confirms the catalytic activity of TET1 in TET1-dCas9 fusion proteins-mediated demethylation at these target sequences. The modular design of the fusion constructs presented here allows for the selective substitution of other chromatin or DNA modifying enzymes and for loci-specific targeting to uncover epigenetic regulatory pathways at gene promoters and other selected genomic regions. Keywords: CRISPR-dCas9, TET1, BRCA1, DNA demethylation, gene activation INTRODUCTION Epigenetic modifications, including DNA methylation, histone covalent modifications and non-coding RNA mechanisms, have attracted a significant amount of attention for the prevention and treatment of different disorders with cancer at the forefront, mainly due to the inherent reversibility of epigenetic states [1–4]. In particular, aberrations in DNA methylation patterns, including hypermethylation of tumour suppressor genes linked to transcriptional silencing, have been extensively studied and described as hallmarks of nearly all types of cancer [4, 5]. The conversion of cytosines to 5-methylcytosine (5-mC), catalyzed by DNA Methyltransferases (DNMTs) was considered as the stably heritable epigenetic trait until the recognition of acquired demethylation in several physiological processes, such as zygotic epigenetic reprogramming, early embryonic development, somatic cell reprogramming, removal of gene imprinting and development of primordial germ cells [6–10]. These demethylation events were subsequently correlated to the existence and activity of a family of Ten-Eleven Translocation dioxygenase (TET1, TET2, TET3) enzymes, which catalytically convert 5-mC to 5-hmC (5-hydroxymethylcytosine) in presence of 2-oxoglutarate and iron (II) excluding the DNMT actions [11–14]. Moreover, all three TETs have been shown to further oxidize 5-hmC to 5-formylcytosince (5-fC) and 5-carboxylcytosine (5-caC) [15, 16]. These modified cytosines are then frequently subjected to deamination, glycosylase dependent excision or DNA repair mechanisms leading to replacement with unmodified cytosines [17, 18]. These findings collectively suggest that TET enzymes are indirectly but actively involved in the process of DNA demethylation [18]. Given the significant role that has been uncovered for DNA hypermethylation in cancer development, there has been a substantial amount of interest in exploring the role of TET enzymes to be used as an eraser of the aberrant DNA methylation marks and modulate the gene expression. Some recent studies have reported novel approaches, such as fusing TET enzymes to the zinc fingers or transcription activation like repeat elements (TALE) of selective demethylation at the hypermethylated promoter of suppressed or inactive genes [19, 20]. Recently, CRISPR-Cas9 (clustered, regularly interspaced, short palindromic repeat-CRISPR associated protein) mediated engineering tools have gained attention of synthetic biologists for their facile yet efficient endogenous genome editing properties [21]. In particular, catalytically inactive Cas9 (dCas9) in combination with single-guide RNA (sgRNA) are frequently being fused to various transcriptional factors (TFs) such as KRAB-repressors or VP64 activators to respectively inactivate (CRISPRi) or activate (CRISPRa) expression of a given gene [22, 23]. However, CRISPR-Cas9 mediated selective epigenome editing has not yet been extensively practiced. Herein, we used dCas9 fused to the TET1 catalytic domain (TET1CD) and co-treated with various combinations of sgRNA to demonstrate targeted epigenetic editing namely demethylation at the promoter of BRCA1, a model tumour suppressor gene. A plethora of clinical studies have extensively documented occurrence of hypermethylation at the BRCA1 promoter leading to gene silencing in nonfamilial breast and ovarian cancers [24–26]. On the contrary, overexpression of BRCA1 was associated with increased apoptosis and inhibition of cell growth in breast and ovarian cancer cells [27, 28]. Silencing of BRCA1 was linked to increased risk of several types of cancer, which are not limited to breast or ovarian types, but also include cervical, pancreatic, uterine, colon, and prostate cancers [29–31]. These studies cumulatively suggest the demand of targeted approaches to induce BRCA1 expression in cancer cells and thus achieve possible therapeutic benefits. Herein, we demonstrate active and on demand targeting of TET1CD to the BRCA1 promoter region using a CRISPR/dCas9 platform in order to decrease DNA methylation, re-activate gene expression and to restore BRCA1 functional activity in breast and cervical cancer. This approach can be expanded as a tool for targeted demethylation of other tumour suppressor genes that are epigenetically silenced in human cancers. RESULTS Construction and expression of TET1CD-dCas9 fusion proteins in cells The constructs were generated by fusing the catalytic domain of TET1 to the N-terminus of deactivated Cas9 tagged with fluorescent reporter EGFP (Figure 1a). We made the fusion proteins either in absence or presence of long linker sequence between TET1CD and dCas9, and defined as TDE-I and TDE-II construct respectively. The transient expression of TDE plasmids in HeLa cells resulted in the full length fusion proteins of ~269 kDa mass (Figure 1b). We also observed the excitation spectra of EGFP in the cell free protein extract of TDE transfected cells using fluorescence spectrometry in both cell lines (Figure S1). TDE-I or TDE-II were co-transfected with different combinations of sequence-specific sgRNAs (Figure 1c). Transient transfection efficiency with TDE-I and TDE-II reached respectively up to 80.8% (Figure 1d) and 84.6% (data not shown) in HeLa cells. In comparison, transfection efficiency with TDE-I and TDE-II reached up to 53.8% (Figure 1e) and 56.2% (data not shown) in MCF7 cells. Per design, upon co-transfection TDE and sgRNAs could be targeted to specific sequences at the BRCA1 promoter. [Figure: The modular design of CRISPR-dCas9 system for TET1 mediated targeting at BRCA1 promotera. Schematic illustration of the deactivated Cas9 (dCas9) and TET1 catalytic domain (TET1CD) fusion proteins (TDEs). b. Western blot analysis demonstrates production of intact TDE-I and TDE-II (~269 kD) fusion proteins, as observed in lane-1 and lane-2 respectively. c. Schematic of single guided RNA sequences, specific to different loci of the BRCA1 promoter target region (d, e). Representative fluorescent micrographs showing the transfection rate of TDE-I in d. HeLa and e. MCF7 cells] Selective demethylation of BRCA1 promoter in HeLa cells upon transfection with TET1CD-dCas9 and sgRNAs Next, we quantitatively determined the extent of targeted demethylation at regions in BRCA1 promoter using pyrosequencing (please see Figure 2a for the gene map and covered CpG sites). The target promoter region also harbors binding sites for multiple BRCA1 high-confidence TFs, as identified by the TRANSFAC TFs binding site prediction tool (Biobase). In this section, we report different levels of demethylation at the target CpG sites, which resulted from the combined treatment of sgRNAs with TDE-I or TDE-II in HeLa or MCF7 cells, compared to the TDE

Read the complete text